Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.39 |
| ▸ | PARP1 | P09874 | 6/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.32 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3744568 | 0.88 | SRC (0.38) | PARP1KDM4EMEN1ALOX15KMT2A | |
| SCHEMBL7657136 | 0.79 | HTR2A (0.38) | PARP10PARP1PARP11KDM1AHTR2C | |
| SCHEMBL8644587 | 0.79 | HTR2C (0.38) | PARP10PARP1PARP11KDM1AHTR2C | |
| SCHEMBL30664964 | 0.79 | HTR2A (0.38) | PARP10PARP1PARP11KDM1AHTR2C | |
| SCHEMBL4624962 | 0.79 | DRD2 (0.37) | PARP10PARP1PARP11KDM4EHSD17B10 | |
| SCHEMBL1870062 | 0.74 | PARP10 (0.43) | PARP10PARP1PARP11MEN1KMT2A | |
| SCHEMBL26656329 | 0.72 | PNMT (0.38) | PARP10PARP1PARP11KDM4EKDM1A | |
| SCHEMBL7659242 | 0.72 | HTR2A (0.45) | PARP10PARP1KDM4EMEN1ALOX15 | |
| SCHEMBL8090872 | 0.71 | ADRA2A (0.47) | KDM4EMEN1ALOX15KMT2AHSD17B10 | |
| SCHEMBL11880436 | 0.71 | PARP10 (0.41) | PARP10PARP1PARP11KDM4EHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024944-A1 | COMPOUNDS TARGETING MUTANT CALRETICULIN | MYELOPRO DIAGNOSTICS AND RESEARCH GMBH (AT) | 2022-01-27 | — | — | US | disclosed |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9475806-B2 | Complement factor B inhibitors and uses there of | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| US-20160024079-A1 | Complement Factor B inhibitors and uses there of | NOVARTIS AG (CH) | 2016-01-28 | — | — | US | disclosed |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9056874-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-11-07 | — | — | US | disclosed |
| US-6413971-B1 | ANTIPROLIFERATIVE, -CARCINOGENIC, -TUMOR AND -DIABETIC AGENTS; BINDING TO OR MODULATING THE HUMAN KINASE INSERT-DOMAIN-CONTAINING RECEPTOR (KDR) OR THE MURINE FETAL LIVER KINASE 1 (FLK-1) RECEPTOR; VASCULOGENESIS; ANGIOGENESIS | PFIZER INC | 2002-07-02 | — | — | US | disclosed |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | ARNOLD LEE DANIEL (US) | 2002-04-18 | — | — | US | disclosed |
| EP-0946554-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998023613-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1141633-A | 4-heterocyclic substituted quinazoline derivatives, process for their preparation and their use as anticancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, TFPI, TFPI2 | PARP10 597/4885PARP1 546/4885PARP11 418/4885 |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | REV1, DPYD, CCNA1 | PARP10 240/4885PARP1 62/4885PARP11 33/4885 |
| US-20160024079-A1 | Complement Factor B inhibitors and uses there of | CFB, CFH, CFD | PARP10 1923/4885PARP1 1431/4885PARP11 1769/4885 |
| US-20220024944-A1 | COMPOUNDS TARGETING MUTANT CALRETICULIN | CALR, MCL1, CALD1 | PARP10 3227/4885PARP1 3932/4885PARP11 2888/4885 |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | PARP10 548/4885PARP1 1468/4885PARP11 614/4885 |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | PARP10 548/4885PARP1 1468/4885PARP11 614/4885 |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, C5, TFPI | PARP10 484/4885PARP1 474/4885PARP11 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.